Makuch Marcin, Makuch Marcelina, Krzewicka-Romaniuk Ewa, Dzida Grzegorz. Sodium-glucose co-transporter 2 inhibitors – a review article. Journal of Education, Health and Sport. 2019;9(9):42-49. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.3372353 http://ojs.ukw.edu.pl/index.php/johs/article/view/7297 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017). 1223 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Authors 2019; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 05.08.2019. Revised: 15.08.2019. Accepted: 20.08.2019. Sodium-glucose co-transporter 2 inhibitors – a review article Marcin Makuch1, Marcelina Makuch2, Ewa Krzewicka-Romaniuk3, Grzegorz Dzida1 1 Chair and Department of Internal Medicine, Medical University of Lublin, Poland 2 Chair and Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland 3 Department of Pathophysiology, Medical University of Lublin, Poland Corresponding author: Marcin Makuch, ul. Staszica 16, 20-081 Lublin, Poland, e- mail: marcinm45@gmail.com Abstract: Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus. An alternative strategy is to enhance urinary glucose excretion by targeting renal sodium-glucose co-transporters (SGLTs). Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce blood glucose by increasing urinary glucose excretion and present a valuable therapeutic option for the treatment of type 2 diabetes. Presently, clinically available SGLT2 inhibitors include canagliflozin, dapagliflozin and empagliflozin [1, 2]. Keywords: sodium-glucose co-transporter 2 inhibitors, glucose, type 2 diabetes, cardiovascular effects